Skip to main content
Premium Trial:

Request an Annual Quote

Skyline Dx: Merlin Assay

Skyline Dx launched the Merlin Assay for melanoma as a laboratory-developed test available through its CLIA/CAP facility in San Diego. According to the Rotterdam, Netherlands-based company, a recently published study found the test could reduce up to 42 percent of surgical interventions in patients diagnosed with melanoma. The assay was developed as a result of the Falcon R&D Program, a partnership between clinicians and academia to develop tools for optimizing the clinical pathway of melanoma patients. 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.